Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: prognostic relevance

Human Pathology

Volumn 38, Issue 1, 2007, Pages 26-34

  Peiró, Gloria ^a   Aranda, Francisco I ^a   Adrover, Encarnal ^a   Niveiro, María ^a   Alenda, Cristina ^a   Payá, Artemio ^a   Seguí, Javier ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

Breast carcinoma; CISH; FISH; HER2; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CHROMOGENIC IN SITU HYBRIDIZATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE OVEREXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RELIABILITY; SURVIVAL TIME; TUMOR NECROSIS; UNIVARIATE ANALYSIS;

ADULT; AGED; ALGORITHMS; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIERS ESTIMATE; KI-67 ANTIGEN; LYMPH NODES; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 33845286926     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2006.07.013     Document Type: Article

References (36)

1. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
2. Peiro G., Mayr D., Hillemanns P., Lohrs U., and Diebold J. Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome. Mod Pathol 17 (2004) 227-287
3. Dougall W.C., Qian X., Peterson N.C., Miller M.J., Samanta A., and Greene M.I. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9 (1994) 2109-2123
4. Jacobs T.W., Gown A.M., Yaziji H., Barnes M.J., and Schnitt S.J. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 17 (1999) 1974-1982
5. Kakar S., Puangsuvan N., Stevens J.M., et al. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn 5 (2000) 199-207
6. Lebeau A., Deimling D., Kaltz C., et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19 (2001) 354-363
7. Owens M.A., Horten B.C., Da M., and Silva M. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5 (2004) 63-69
8. Xu R., Perle M.A., Inghirami G., Chan W., Delgado Y., and Feiner H. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol 15 (2002) 116-124
9. van de Vijver M. Emerging technologies for HER2 testing. Oncology 63 Suppl 1 (2002) 33-38
10. Press M.F., Slamon D.J., Flom K.J., Park J., Zhou J.Y., and Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20 (2002) 3095-3105
11. Yaziji H., Goldstein L.C., Barry T.S., et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291 (2004) 1972-1977
12. Tubbs R.R., Pettay J.D., Roche P.C., Stoler M.H., Jenkins R.B., and Grogan T.M. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 19 (2001) 2714-2721
13. Tanner M., Gancberg D., Di Leo A., et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 157 (2000) 1467-1472
14. Zhao J., Wu R., Au A., Marquez A., Yu Y., and Shi Z. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol 15 (2002) 657-665
15. Park K., Kim J., Lim S., Han S., and Lee J.Y. Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray. Mod Pathol 16 (2003) 937-943
16. Madrid M.A., and Lo R.W. Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status. Breast Cancer Res 6 (2004) R593-R600
17. Isola J., Tanner M., Forsyth A., Cooke T.G., Watters A.D., and Bartlett J.M. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 10 (2004) 4793-4798
18. Pellikainen J., Naukkarinen A., Ropponen K., et al. Expression of HER2 and its association with AP-2 in breast cancer. Eur J Cancer 40 (2004) 1485-1495
19. Vera-Roman J.M., and Rubio-Martinez L.A. Comparative assays for the HER-2/neu oncogene status in breast cancer. Arch Pathol Lab Med 128 (2004) 627-633
20. Gong Y., Gilcrease M., and Sneige N. Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. Mod Pathol 18 (2005) 1015-1021
21. Saez A., Andreu F.J., Segui M.A., et al. HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases. Breast 15 (2006) 519-527
22. Loring P., Cummins R., O'Grady A., and Kay E.W. HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization. Appl Immunohistochem Mol Morphol 13 (2005) 194-200
23. Hanna W.M., and Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol 19 (2006) 481-487
24. Joensuu H., Isola J., Lundin M., et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 9 (2003) 923-930
25. Chang E., Lee A., Lee E., et al. HER-2/neu oncogene amplification by chromogenic in situ hybridization in 130 breast cancers using tissue microarray and clinical follow-up studies. J Korean Med Sci 19 (2004) 390-396
26. Dandachi N., Dietze O., and Hauser-Kronberger C. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer. Anticancer Res 24 (2004) 2401-2406
27. Press M.F., Bernstein L., Thomas P.A., et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15 (1997) 2894-2904
28. Volpi A., Nanni O., De Paola F., et al. HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer. J Clin Oncol 21 (2003) 2708-2712
29. Ring B.Z., Seitz R.S., Beck R., et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 24 (2006) 3039-3047
30. Pauletti G., Dandekar S., Rong H., et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18 (2000) 3651-3664
31. Elkin E.B., Weinstein M.C., Winer E.P., Kuntz K.M., Schnitt S.J., and Weeks J.C. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 22 (2004) 854-863
32. Wang S., Hossein Saboorian M., Frenkel E.P., et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol 15 (2002) 137-145
33. Lal P., Salazar P.A., Ladanyi M., and Chen B. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. J Mol Diagn 5 (2003) 155-159
34. Tubbs R., Pettay J., Hicks D., et al. Novel bright field molecular morphology methods for detection of HER2 gene amplification. J Mol Histol 35 (2004) 589-594
35. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
36. Lehr H.A., Jacobs T.W., Yaziji H., Schnitt S.J., and Gown A.M. Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis. Am J Clin Pathol 115 (2001) 814-822